Joan Bailey, MD
Endocrinology, Diabetes & Metabolism · Phoenix, AZNPI 1184615023
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $253,108 of the $316,443 with a category attached, or 80.0%. Lilly USA, LLC accounts for 91.7% of it on its own, with 48 other manufacturers making up the rest. Reporting peaked in 2019 at $77,244 and has fallen 69.2% since, to $23,806 in 2025. Among endocrinology, diabetes & metabolism clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,102 payments — averaging $287.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$290K
- AstraZeneca$16K
- Corcept Therapeutics$3K
- Amgen$960
- AbbVie$715
- Dexcom, Inc.$593
- plus $5K from 43 others
What the payments were for
- Consulting fees$4,6501%
- Speaking & faculty fees$253,10880%
- Travel & lodging$41,83413%
- Food & beverage$16,8335%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$129,983
- TRULICITY$86,591
- FARXIGA$14,943
- Korlym$2,742
- EVENITY$238
- Omnipod$134
- CRENESSITY$132
- Minimed 530G$119
- Kerendia$117
- DEXCOM G7 GSS (161)$102
How this compares
$316,443 in reported general payments places this provider in the 95th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 132 | $203,756 |
| MounjaroTirzepatide | 120 | $158,295 |
| OzempicSemaglutide | 91 | $128,420 |
| FarxigaDapagliflozin Propanediol | 65 | $101,645 |
| JardianceEmpagliflozin | 77 | $98,346 |
| ForteoTeriparatide | 11 | $44,305 |
| SynthroidLevothyroxine Sodium | 332 | $36,589 |
| Bydureon BciseExenatide Microspheres | 17 | $31,192 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $29,401 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $23,307 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $22,628 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $19,796 |
| JanuviaSitagliptin Phosphate | 15 | $15,836 |
| Humalog Kwikpen U-100Insulin Lispro | 53 | $15,802 |
| HumalogInsulin Lispro | 45 | $11,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog, Insulin Lispro | $290,198 | $420,043326 claims |
| Novo NordiskOzempic, Tresiba | $514 | $133,973102 claims |
| AstraZenecaFarxiga | $15,892 | $101,64565 claims |
| Boehringer IngelheimJardiance | $132 | $98,34677 claims |
| AbbVieSynthroid | $715 | $36,589332 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $149 | $9,329653 claims |
| IBSA Pharma Inc.Tirosint | $30 | $2,81713 claims |
| Sanofi-aventis U.S. LLCLantus | $557 | $2,33914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Phoenix
- Kevin YuenPhoenix$404K
- Anna BoronPhoenix$32K
- Kari EdlingPhoenix$23K
- James DeerPhoenix$13K
- Lory BarazPhoenix$10K
- Sathya JyothinagaramPhoenix$10K
- Philip LevyPhoenix$9K
- Richard ArakakiPhoenix$6K
- Yasmin AkhunjiPhoenix$5K
- Ahmad Al MaradniPhoenix$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.